INTERLEUKIN-17 OR TNF BLOCKADE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AFTER WITHDRAWAL OF AT LEAST ONE TNF INHIBITOR

被引：0
|
作者：
Tellenbach, Christoph [1 ]
Micheroli, Raphael [1 ]
Buerki, Kristina [1 ]
Scherer, Almut [2 ]
Nissen, Michael [3 ]
Zufferey, Pascal [4 ]
Exer, Pascale
Moeller, Burkhard [5 ]
Kyburz, Diego [6 ]
Ciurea, Adrian [1 ]
机构：
[1] Univ Hosp Zurich, Zurich, Switzerland
[2] SCQM Fdn, Zurich, Switzerland
[3] Univ Hosp Geneva, Geneva, Switzerland
[4] Univ Hosp, Lausanne, Switzerland
[5] Inselspital Bern, Bern, Switzerland
[6] Univ Hosp, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.2427
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0237
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [21] THE IMPACT OF EXTRA-ARTICULAR MANIFESTATIONS ON THE CHOICE OF TNF INHIBITOR IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN THE BSRBR-AS REGISTER
    Derakhshan, Mohammad H.
    Dean, Linda
    Jones, Gareth T.
    Macfarlane, Gary
    Siebert, Stefan
    Gaffney, Karl
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 194 - 195
  • [22] Effects Of Smoking In Patients With Axial Spondyloarthritis - Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis - Receiving Anti-TNF therapy
    Pehlivan, Ozlem
    Yalcinkaya, Yasemin
    Huseyinsinoglu, Nihat
    Kanitez, Nilufer Alpay
    Erer, Burak
    Kamali, Sevil
    Inanc, Murat
    Aral, Orhan
    Gul, Ahmet
    Ocal, Lale
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1048 - S1049
  • [23] What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
    Heberg, Jette
    Georgiadis, Stylianos
    Pons, Marion
    Loft, Anne Gitte
    Michelsen, Brigitte
    Linde, Louise
    DiGuiseppe, Daniela
    Rasmussen, Simon Horskjaer
    Kazemi, Mehrdad
    Macfarlane, Gary
    Jones, Gareth
    Laas, Karin
    Vorobjov, Sigrid
    Castrejon, Isabel
    Rotar, Ziga
    Perdan-Pikmajer, Katja
    Senolt, Ladislav
    Baranova, Jana
    Glintborg, Bente
    Ciurea, Adrian
    Bernardes, Miguel
    Valente, Paula
    Gudbjornsson, Bjorn
    Grondal, Gerdur
    Bakland, Gunnstein
    Codreanu, Catalin
    Mogosan, Corina
    Iannone, Florenzo
    Caporali, Roberto
    Wallman, Johan Karlsson
    Rantalaiho, Vappu
    Peltomaa, Ritva
    Pavelka, Karel
    Horak, Pavel
    Almeida, Diogo Esperanca
    Rodrigues, Sara Dias
    Oernbjerg, Lykke
    Ostergaard, Mikkel
    Hetland, Merete
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3585 - 3588
  • [24] EFFICACY OF COMEDICATION OF CONVENTIONAL SYNTHETIC DMARDS WITH TNF BLOCKERS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
    Ben Abdelghani, K.
    Gzam, Y.
    Fazaa, A.
    Miladi, S.
    Ouenniche, K.
    Kassab, S.
    Souabni, L.
    Chekili, S.
    Laatar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1609 - 1610
  • [25] The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis
    Bornstein, G.
    Lidar, M.
    Langevitz, P.
    Fardman, A.
    Ben-Zvi, I.
    Grossman, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (02) : 228 - 232
  • [26] Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis
    Zhao, Sizheng Steven
    Jones, Gareth T.
    Hughes, David M.
    Moots, Robert J.
    Goodson, Nicola J.
    RHEUMATOLOGY, 2021, 60 (12) : 5734 - 5742
  • [27] FACTORS ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING IL-17A INHIBITOR OR TNF INHIBITOR THERAPY: A POST-HOC ANALYSIS OF THE SURPASS STUDY
    Poddubnyy, D.
    Braun, J.
    Machado, P.
    Navarro-Compan, V
    Gensler, L. S.
    Hermann, K. G.
    Quebe-Fehling, E.
    Pieterse, C. C.
    Readie, A.
    Gaillez, C.
    Baraliakos, X.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 71 - 71
  • [28] Change in disease activity is associated with TNF-α inhibitor serum levels in patients with axial spondyloarthritis in daily clinical practice
    de Wolff, L.
    Wink, F. R.
    Bootsma, H.
    Arends, S.
    Spoorenberg, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (03) : 489 - 494
  • [29] Use of TNF inhibition therapy in patients with axial spondyloarthritis [Einsatz von TNF-α-Blocker-Therapie bei Patienten mit axialer Spondyloarthritis]
    Kiltz U.
    Zeitschrift für Rheumatologie, 2015, 74 (3) : 263 - 264
  • [30] Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort
    Ciurea, Adrian
    Exer, Pascale
    Weber, Ulrich
    Tamborrini, Giorgio
    Steininger, Beate
    Kissling, Rudolf O.
    Bernhard, Juerg
    Scherer, Almut
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
12345